{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:47:54Z","timestamp":1790092074413,"version":"4.0.1"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005189","name":"Blood Cancer United","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bbcan.2026.189599","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:16:04Z","timestamp":1777522564000},"page":"189599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genetic mutations and inhibitors of p300 and CBP"],"prefix":"10.1016","volume":"1881","author":[{"given":"Agnieszka","family":"Robaszkiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7337","key":"10.1016\/j.bbcan.2026.189599_bb0005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189599_bb0010","doi-asserted-by":"crossref","unstructured":"M. Luo, Y. Zhang, Z. Xu, S. Lv, Q. Wei, i Q. Dang, \u201eExperimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutation\u201d, Mol. Med., 29, 1, 7, 2023, doi:https:\/\/doi.org\/10.1186\/s10020-023-00608-7.","DOI":"10.1186\/s10020-023-00608-7"},{"issue":"Supplement 1","key":"10.1016\/j.bbcan.2026.189599_bb0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2024-208876","article-title":"Differential role of Crebbp missense and truncating mutations in the malignant transformation of germinal center B cells","volume":"144","author":"Yu","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189599_bb0020","article-title":"CREBBP\/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2\/CSF1 axis","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189599_bb0035","doi-asserted-by":"crossref","unstructured":"P. Gou i W. Zhang, \u201eProtein lysine acetyltransferase CBP\/p300: a promising target for small molecules in cancer treatment\u201d, Biomed. Pharmacother., 171, 116130, 2024, doi:https:\/\/doi.org\/10.1016\/j.biopha.2024.116130.","DOI":"10.1016\/j.biopha.2024.116130"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189599_bb0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nchembio.2217","article-title":"Structure of p300 in complex with acyl-CoA variants","volume":"13","author":"Kaczmarska","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbcan.2026.189599_bb0045","doi-asserted-by":"crossref","unstructured":"J. Maksimoska, D. Segura-Pe\u00f1a, P. A. Cole, i R. Marmorstein, \u201eStructure of the p300 histone acetyltransferase bound to acetyl-coenzyme A and its analogues\u201d, Biochemistry, 53, 21, 3415\u20133422, 2014, doi:https:\/\/doi.org\/10.1021\/bi500380f.","DOI":"10.1021\/bi500380f"},{"key":"10.1016\/j.bbcan.2026.189599_bb0050","doi-asserted-by":"crossref","unstructured":"Z.-X. He, B.-F. Wei, X. Zhang, Y.-P. Gong, L.-Y. Ma, i W. Zhao, \u201eCurrent development of CBP\/p300 inhibitors in the last decade\u201d, Eur. J. Med. Chem., 209, 112861, 2021, doi:https:\/\/doi.org\/10.1016\/j.ejmech.2020.112861.","DOI":"10.1016\/j.ejmech.2020.112861"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189599_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-39735-4","article-title":"Epigenetic mechanisms to propagate histone acetylation by p300\/CBP","volume":"14","author":"Kikuchi","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189599_bb0060","doi-asserted-by":"crossref","unstructured":"E. Yaz\u0131c\u0131 i J. McIntyre, \u201eThe complex network of p300\/CBP regulation: interactions, posttranslational modifications, and therapeutic implications\u201d, J. Biol. Chem., 301, 11, 110715, 2025, doi:https:\/\/doi.org\/10.1016\/j.jbc.2025.110715.","DOI":"10.1016\/j.jbc.2025.110715"},{"key":"10.1016\/j.bbcan.2026.189599_bb0065","doi-asserted-by":"crossref","unstructured":"A. R. Waddell, H. Huang, i D. Liao, \u201eCBP\/p300: critical co-activators for nuclear steroid hormone receptors and emerging therapeutic targets in prostate and breast cancers\u201d, Cancers 13, 12, 2872, 2021, doi:https:\/\/doi.org\/10.3390\/cancers13122872.","DOI":"10.3390\/cancers13122872"},{"key":"10.1016\/j.bbcan.2026.189599_bb0070","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1038\/s41467-023-41245-2","article-title":"TAZ2 truncation confers overactivation of p300 and cellular vulnerability to HDAC inhibition","volume":"14","author":"Xu","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189599_bb0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-35375-2","article-title":"Structural insights into p300 regulation and acetylation-dependent genome organisation","volume":"13","author":"Ibrahim","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189599_bb0080","doi-asserted-by":"crossref","unstructured":"E. Karlsson, F. A. Sorgenfrei, E. Andersson, J. Dogan, P. Jemth, i C. N. Chi, \u201eThe dynamic properties of a nuclear coactivator binding domain are evolutionarily conserved\u201d, Commun. Biol., 5, 1, 286, 2022, doi:https:\/\/doi.org\/10.1038\/s42003-022-03217-y.","DOI":"10.1038\/s42003-022-03217-y"},{"key":"10.1016\/j.bbcan.2026.189599_bb0085","doi-asserted-by":"crossref","unstructured":"B. M. Dancy i P. A. Cole, \u201eProtein lysine acetylation by p300\/CBP\u201d, Chem. Rev., 115, 6, 2419\u20132452, 2015, doi:https:\/\/doi.org\/10.1021\/cr500452k.","DOI":"10.1021\/cr500452k"},{"key":"10.1016\/j.bbcan.2026.189599_bb0090","doi-asserted-by":"crossref","unstructured":"E. Kalkhoven, H. Teunissen, A. Houweling, C. P. Verrijzer, i A. Zantema, \u201eThe PHD type zinc finger is an integral part of the CBP acetyltransferase domain\u201d, Mol. Cell. Biol., 22, 7, 1961\u20131970, 2002, doi:https:\/\/doi.org\/10.1128\/MCB.22.7.1961-1970.2002.","DOI":"10.1128\/MCB.22.7.1961-1970.2002"},{"key":"10.1016\/j.bbcan.2026.189599_bb0100","doi-asserted-by":"crossref","unstructured":"E. Karlsson, A. Lindberg, E. Andersson, i P. Jemth, \u201eHigh affinity between CREBBP \/p300 and NCOA evolved in vertebrates\u201d, Protein Sci., 29, 7, 1687\u20131691, 2020, doi:https:\/\/doi.org\/10.1002\/pro.3868.","DOI":"10.1002\/pro.3868"},{"key":"10.1016\/j.bbcan.2026.189599_bb0105","doi-asserted-by":"crossref","unstructured":"O. Oka et al., \u201eInteraction of the transactivation domain of B-Myb with the TAZ2 domain of the coactivator p300: molecular features and properties of the complex\u201d, PLoS One, t. 7, 12, e52906, 2012, doi:https:\/\/doi.org\/10.1371\/journal.pone.0052906.","DOI":"10.1371\/journal.pone.0052906"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189599_bb0110","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/s41594-018-0114-9","article-title":"The ZZ domain of p300 mediates specificity of the adjacent HAT domain for histone H3","volume":"25","author":"Zhang","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bbcan.2026.189599_bb0115","doi-asserted-by":"crossref","unstructured":"J. Van Gils, F. Magdinier, P. Fergelot, i D. Lacombe, \u201eRubinstein-Taybi syndrome: a model of epigenetic disorder\u201d, Genes, 12, 7, 968, 2021, doi:https:\/\/doi.org\/10.3390\/genes12070968.","DOI":"10.3390\/genes12070968"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189599_bb0120","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ajmg.a.38603","article-title":"Benign and malignant tumors in Rubinstein\u2013Taybi syndrome","volume":"176","author":"Boot","year":"2018","journal-title":"Am. J. Med. Genet. A"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189599_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041219","article-title":"The role of CREBBP\/EP300 and its therapeutic implications in hematological malignancies","volume":"15","author":"Zhu","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189599_bb0130","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0092-8674(00)81165-4","article-title":"Gene dosage\u2013dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300","volume":"93","author":"Yao","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189599_bb0135","doi-asserted-by":"crossref","unstructured":"V. I. Rebel, A. L. Kung, E. A. Tanner, H. Yang, R. T. Bronson, i D. M. Livingston, \u201eDistinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal\u201d, Proc. Natl. Acad. Sci., 99, 23, 14789\u201314794, 2002, doi:https:\/\/doi.org\/10.1073\/pnas.232568499.","DOI":"10.1073\/pnas.232568499"},{"key":"10.1016\/j.bbcan.2026.189599_bb0140","doi-asserted-by":"crossref","unstructured":"K. Gronkowska i A. Robaszkiewicz, \u201eGenetic dysregulation of EP300 in cancers in light of cancer epigenome control \u2013 targeting of p300-proficient and -deficient cancers\u201d, Mol. Ther. Oncol., 32, 4, 200871, 2024, doi:https:\/\/doi.org\/10.1016\/j.omton.2024.200871.","DOI":"10.1016\/j.omton.2024.200871"},{"key":"10.1016\/j.bbcan.2026.189599_bb0145","doi-asserted-by":"crossref","unstructured":"Q. Chen, B. Yang, X. Liu, X. D. Zhang, L. Zhang, i T. Liu, \u201eHistone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents\u201d, Theranostics, 12, 11, 4935\u20134948, 2022, doi:https:\/\/doi.org\/10.7150\/thno.73223.","DOI":"10.7150\/thno.73223"},{"key":"10.1016\/j.bbcan.2026.189599_bb0150","doi-asserted-by":"crossref","unstructured":"L. Zhu, W. Bai, Q. Cheng, i J. Fang, \u201eZNF384-related fusion genes in acute lymphoblastic leukemia\u201d, Cancer Control, 30, 10732748231182787, 2023, doi:https:\/\/doi.org\/10.1177\/10732748231182787.","DOI":"10.1177\/10732748231182787"},{"key":"10.1016\/j.bbcan.2026.189599_bb0155","article-title":"The prognostic significance of ZNF384 fusions in adult Ph-negative B-cell precursor acute lymphoblastic leukemia: a comprehensive cohort study from a single Chinese center","volume":"11","author":"Qin","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189599_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115798","article-title":"I-CBP112 declines overexpression of ATP-binding cassette transporters and sensitized drug-resistant MDA-MB-231 and A549 cell lines to chemotherapy drugs","volume":"168","author":"Strachowska","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189599_bb0165","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-21-0385","article-title":"EP300 selectively controls the enhancer landscape of MYCN -amplified neuroblastoma","volume":"12","author":"Durbin","year":"2022","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189599_bb0170","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl4618","article-title":"KIX domain determines a selective tumor-promoting role for EP300 and its vulnerability in small cell lung cancer","volume":"8","author":"Kim","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2026.189599_bb0175","doi-asserted-by":"crossref","unstructured":"M. L. Swift, K. Beishline, i J. Azizkhan-Clifford, \u201eSp1-dependent recruitment of the histone acetylase p300 to DSBs facilitates chromatin remodeling and recruitment of the NHEJ repair factor Ku70\u201d, DNA Repair, 105, 103171, 2021, doi:https:\/\/doi.org\/10.1016\/j.dnarep.2021.103171.","DOI":"10.1016\/j.dnarep.2021.103171"},{"key":"10.1016\/j.bbcan.2026.189599_bb0180","doi-asserted-by":"crossref","unstructured":"W. S. Ramadan, S. Ahmed, L. Lozon, S. Mouffak, W. Mansour, i R. El-Awady, \u201e22P emerging role of histone acetyltransferase CBP in breast cancer cells undergoing DNA damage\u201d, ESMO Open, 8, 1, 100988, 2023, doi:https:\/\/doi.org\/10.1016\/j.esmoop.2023.100988.","DOI":"10.1016\/j.esmoop.2023.100988"},{"key":"10.1016\/j.bbcan.2026.189599_bb0185","doi-asserted-by":"crossref","unstructured":"I. Dutto, C. Scalera, i E. Prosperi, \u201eCREBBP and p300 lysine acetyl transferases in the DNA damage response\u201d, Cell. Mol. Life Sci., 75, 8, 1325\u20131338, 2018, doi:https:\/\/doi.org\/10.1007\/s00018-017-2717-4.","DOI":"10.1007\/s00018-017-2717-4"},{"key":"10.1016\/j.bbcan.2026.189599_bb0190","doi-asserted-by":"crossref","unstructured":"H. Ogiwara et al., \u201eTargeting p300 addiction in CBP -deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression\u201d, Cancer Discov., 6, nr 4, 430\u2013445, 2016, doi:https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0754.","DOI":"10.1158\/2159-8290.CD-15-0754"},{"key":"10.1016\/j.bbcan.2026.189599_bb0195","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.canlet.2021.09.002","article-title":"CREBBP cooperates with the cell cycle machinery to attenuate Chidamide sensitivity in relapsed\/refractory diffuse large B-cell lymphoma","volume":"521","author":"Sun","year":"2021","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189599_bb0200","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.immuni.2019.08.006","article-title":"Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma","volume":"51","author":"Meyer","year":"2019","journal-title":"Immunity"},{"issue":"7180","key":"10.1016\/j.bbcan.2026.189599_bb0205","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nature06546","article-title":"The structural basis of protein acetylation by the p300\/CBP transcriptional coactivator","volume":"451","author":"Liu","year":"2008","journal-title":"Nature"},{"issue":"7674","key":"10.1016\/j.bbcan.2026.189599_bb0210","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nature24028","article-title":"Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours","volume":"550","author":"Lasko","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189599_bb0215","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/emboj\/20.6.1331","article-title":"p300\/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2","volume":"20","author":"Ito","year":"2001","journal-title":"EMBO J."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189599_bb0220","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nbt.3199","article-title":"Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers","volume":"33","author":"Hilton","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbcan.2026.189599_bb0225","doi-asserted-by":"crossref","unstructured":"J. H. Shrimp, C. Grose, S. R. T. Widmeyer, A. L. Thorpe, A. Jadhav, i J. L. Meier, Chemical control of a CRISPR-Cas9 acetyltransferase, ACS Chem. Biol., 13, 2, 455\u2013460, 2018, doi:https:\/\/doi.org\/10.1021\/acschembio.7b00883.","DOI":"10.1021\/acschembio.7b00883"},{"key":"10.1016\/j.bbcan.2026.189599_bb0230","doi-asserted-by":"crossref","unstructured":"S. Picaud et al., Generation of a selective small molecule inhibitor of the CBP\/p300 bromodomain for leukemia therapy, Cancer Res., t. 75, 23, 5106\u20135119, 2015, doi:https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0236.","DOI":"10.1158\/0008-5472.CAN-15-0236"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189599_bb0235","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/ng.3076","article-title":"Genetic landscape of esophageal squamous cell carcinoma","volume":"46","author":"Gao","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2026.189599_bb0245","doi-asserted-by":"crossref","unstructured":"H. Yang et al., Crebbp kat domain missense mutations alter its dynamic loading onto chromatin and create a transcription factor sink, Blood, t. 140, Supplement 1, 8768\u20138769, 2022, doi:https:\/\/doi.org\/10.1182\/blood-2022-166230.","DOI":"10.1182\/blood-2022-166230"},{"key":"10.1016\/j.bbcan.2026.189599_bb0250","doi-asserted-by":"crossref","unstructured":"H. Yang et al., Blunted CD40-responsive enhancer activation in CREBBP -mutant lymphomas can be restored by enforced CD4 T-cell engagement, Blood, t. 146, 2, 191\u2013205, 2025, doi:https:\/\/doi.org\/10.1182\/blood.2024026664.","DOI":"10.1182\/blood.2024026664"},{"key":"10.1016\/j.bbcan.2026.189599_bb0255","doi-asserted-by":"crossref","unstructured":"J. G. M. Rack et al., \u201eThe PHD finger of p300 influences its ability to acetylate histone and non-histone targets\u201d, J. Mol. Biol., t. 426, 24, 3960\u20133972, 2014, doi:https:\/\/doi.org\/10.1016\/j.jmb.2014.08.011.","DOI":"10.1016\/j.jmb.2014.08.011"},{"key":"10.1016\/j.bbcan.2026.189599_bb0260","doi-asserted-by":"crossref","unstructured":"M. Delvecchio, J. Gaucher, C. Aguilar-Gurrieri, E. Ortega, i D. Panne, \u201eStructure of the p300 catalytic core and implications for chromatin targeting and HAT regulation\u201d, Nat. Struct. Mol. Biol., 20, 9, 1040\u20131046, 2013, doi:https:\/\/doi.org\/10.1038\/nsmb.2642.","DOI":"10.1038\/nsmb.2642"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189599_bb0265","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-59531-6","article-title":"CREBBP inactivation sensitizes B cell acute lymphoblastic leukemia to ferroptotic cell death upon BCL2 inhibition","volume":"16","author":"Garcia-Gimenez","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189599_bb0270","doi-asserted-by":"crossref","unstructured":"L. Haery, J. G. Lugo-Pic\u00f3, R. A. Henry, A. J. Andrews, i T. D. Gilmore, \u201eHistone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth\u201d, Mol. Cancer, 13, 1, 29, 2014, doi:https:\/\/doi.org\/10.1186\/1476-4598-13-29.","DOI":"10.1186\/1476-4598-13-29"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189599_bb0275","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/jmg.2004.025080","article-title":"CBP truncating mutations in ovarian cancer","volume":"42","author":"Ward","year":"2005","journal-title":"J. Med. Genet."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189599_bb0280","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1158\/2159-8290.CD-18-0385","article-title":"Crebbp loss drives small cell lung cancer and increases sensitivity to HDAC inhibition","volume":"8","author":"Jia","year":"2018","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189599_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13112592","article-title":"Mutations in CREBBP and EP300 HAT and bromo domains drive hypermutation and predict survival in GI cancers treated with immunotherapy","volume":"13","author":"Gusakova","year":"2025","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189599_bb0295","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/ncb3597","article-title":"Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors","volume":"19","author":"Horton","year":"2017","journal-title":"Nat. Cell Biol."},{"issue":"7757","key":"10.1016\/j.bbcan.2026.189599_bb0300","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the cancer cell line encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"issue":"45","key":"10.1016\/j.bbcan.2026.189599_bb0305","doi-asserted-by":"crossref","first-page":"28201","DOI":"10.1073\/pnas.2002660117","article-title":"Comprehensive characterization of amino acid positions in protein structures reveals molecular effect of missense variants","volume":"117","author":"Iqbal","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189599_bb0310","first-page":"340","article-title":"Next-generation sequencing RNA fusion panel for the diagnosis of haematological malignancies","volume":"57","author":"Ngo","year":"2025","journal-title":"Pathology (Phila.)"},{"key":"10.1016\/j.bbcan.2026.189599_bb0315","doi-asserted-by":"crossref","unstructured":"A. Spa\u0142ek, A. Bartkowska-Chrobok, M. Kuli\u0144ska-Kozak, B. Szymczak, J. Dziaczkowska-Suszek, i G. Helbig, \u201eFatal outcome of a rare acute myeloid leukemia with t(8;16)(p11.2;p13.3) and KAT6A::CREBBP gene fusion in a young man\u201d, Hematol. Transfus. Cell Ther., 46, S410\u2013S414, 2024, doi:https:\/\/doi.org\/10.1016\/j.htct.2024.02.023.","DOI":"10.1016\/j.htct.2024.02.023"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189599_bb0320","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-024-01596-9","article-title":"EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia","volume":"22","author":"Hou","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bbcan.2026.189599_bb0325","doi-asserted-by":"crossref","unstructured":"S. W. Kim, S. Lee, S. Shin, i S.-T. Lee, \u201eRare gene rearrangement t(11;22)(q23;q13)\/ KMT2A-EP300 in therapy-related acute myeloid leukemia: a case report\u201d, Ann. Lab. Med., 42, 6, 693\u2013696, 2022, doi:https:\/\/doi.org\/10.3343\/alm.2022.42.6.693.","DOI":"10.3343\/alm.2022.42.6.693"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189599_bb0330","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/acsmedchemlett.0c00155","article-title":"Discovery of CPI-1612: a potent, selective, and orally bioavailable EP300\/CBP histone acetyltransferase inhibitor","volume":"11","author":"Wilson","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbcan.2026.189599_bb0335","doi-asserted-by":"crossref","unstructured":"M. Alamodi Alghamdi i H. Deshpande, \u201eSelective inhibition of p300 by a novel small molecule EPS496 promotes cell death in vemurafenib-resistant BRAFV600E mutated melanoma cells\u201d, Biochem. Biophys. Res. Commun., 750, 151382, 2025, doi:https:\/\/doi.org\/10.1016\/j.bbrc.2025.151382.","DOI":"10.1016\/j.bbrc.2025.151382"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189599_bb0340","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-47102-0","article-title":"Group 3 medulloblastoma transcriptional networks collapse under domain specific EP300\/CBP inhibition","volume":"15","author":"Shendy","year":"2024","journal-title":"Nat. Commun."},{"issue":"23","key":"10.1016\/j.bbcan.2026.189599_bb0345","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1038\/s41388-022-02327-5","article-title":"Targeting CDCP1 gene transcription coactivated by BRD4 and CBP\/p300 in castration-resistant prostate cancer","volume":"41","author":"Ji","year":"2022","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189599_bb0350","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116764119","article-title":"XP-524 is a dual-BET\/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer","volume":"119","author":"Principe","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189599_bb0355","doi-asserted-by":"crossref","DOI":"10.1101\/2024.05.03.592353","article-title":"Paralogue-selective degradation of the lysine acetyltransferase EP300","author":"Chen","year":"2024","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189599_bb0360","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.chembiol.2020.12.004","article-title":"Targeted degradation of the enhancer lysine acetyltransferases CBP and p300","volume":"28","author":"Vannam","year":"2021","journal-title":"Cell Chem. Biol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189599_bb0365","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1039\/D4MD00969J","article-title":"Development of p300-targeting degraders with enhanced selectivity and onset of degradation","volume":"16","author":"Marsh","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189599_bb0370","doi-asserted-by":"crossref","unstructured":"L. Palaferri, I. Cheng-S\u00e1nchez, C. Nevado, \u201eRecent advances in CBP\/EP300 degraders\u201d, Chimia, 79, nr 3, s. 137\u2013145, 2025, doi:https:\/\/doi.org\/10.2533\/chimia.2025.137.","DOI":"10.2533\/chimia.2025.137"},{"key":"10.1016\/j.bbcan.2026.189599_bb0375","doi-asserted-by":"crossref","unstructured":"T. Wu et al., \u201eDiscovery of a promising CBP\/p300 degrader XYD129 for the treatment of acute myeloid leukemia\u201d, J. Med. Chem., t. 67, nr 11, s. 9194\u20139213, 2024, doi:https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00335.","DOI":"10.1021\/acs.jmedchem.4c00335"},{"key":"10.1016\/j.bbcan.2026.189599_bb0380","doi-asserted-by":"crossref","unstructured":"L. C. Cerchietti et al., \u201eBCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy\u201d, J. Clin. Invest., 120, nr 12, s. 4569\u20134582, 2010, doi:https:\/\/doi.org\/10.1172\/JCI42869.","DOI":"10.1172\/JCI42869"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189599_bb0385","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-021-01060-2","article-title":"The impact of CBP expression in estrogen receptor-positive breast cancer","volume":"13","author":"Ramadan","year":"2021","journal-title":"Clin. Epigenetics"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189599_bb0390","doi-asserted-by":"crossref","DOI":"10.3171\/2024.2.FOCUS244","article-title":"EP300 through upregulating the expression of vimentin to promote the progression of chordoma","volume":"56","author":"Wen","year":"2024","journal-title":"Neurosurg. Focus"},{"key":"10.1016\/j.bbcan.2026.189599_bb0395","doi-asserted-by":"crossref","unstructured":"A. Gupta, M. M. Patnaik, i H. V. Naina, \u201eMYST3\/CREBBP rearranged acute myeloid leukemia after adjuvant chemotherapy for breast cancer\u201d, Case Rep. Oncol. Med., 2014 1\u20133, 2014, doi:https:\/\/doi.org\/10.1155\/2014\/361748.","DOI":"10.1155\/2014\/361748"},{"key":"10.1016\/j.bbcan.2026.189599_bb0400","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025031924","article-title":"Inhibition of p300\/CREBBP catalytic activity drives context-dependent transcriptional activation in AML","author":"Meyerh\u00f6fer","year":"2026","journal-title":"Blood J."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:33:38Z","timestamp":1785072818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26000715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0304419X26000715"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189599","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic mutations and inhibitors of p300 and CBP","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189599"}}